Comparative Pharmacology
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE W LEVONORDEFRIN versus LIGNOSPAN FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE W LEVONORDEFRIN versus LIGNOSPAN FORTE.
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN vs LIGNOSPAN FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Articaine hydrochloride is a local anesthetic of the amide type that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. Levonordefrin is a sympathomimetic vasoconstrictor that acts on alpha-adrenergic receptors to produce local vasoconstriction, reducing absorption of the anesthetic and prolonging its effect.
Lidocaine and prilocaine stabilize neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
For local anesthesia: 1-5 mL of 2% solution (20 mg/mL) with levonordefrin 1:20,000, infiltrated locally; maximum single dose: 3.5 mg/kg (not to exceed 200 mg total).
Adults: 2% lidocaine with 1:100,000 epinephrine, max 7 mg/kg lidocaine (500 mg) without epinephrine or 4.5 mg/kg (300 mg) with epinephrine; for dental infiltration or nerve block, 1-2 mL per site.
None Documented
None Documented
Articaine: approximately 1-2 hours (terminal half-life). Levonordefrin: not separately reported; vasoconstrictor effect duration supports anesthetic action. Clinical context: half-life is short, reflecting rapid metabolism by plasma esterases; clinical duration of anesthesia is prolonged by levonordefrin.
Terminal elimination half-life of lidocaine: 1.5–2 hours; in hepatic impairment or heart failure, may extend to >4 hours. For the vasoconstrictor (epinephrine), half-life is approximately 2 minutes due to rapid uptake and metabolism.
Renal: primarily as metabolites (hydroxy derivatives) and unchanged drug; approximately 90% eliminated in urine as metabolites, <5% unchanged. Biliary/fecal: minor, <10%.
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and other conjugates): ~90%; biliary/fecal: <10% as unchanged drug.
Category C
Category C
Local Anesthetic with Vasoconstrictor
Local Anesthetic with Vasoconstrictor